Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
GEO-CM04S1 · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| COVID-19 Vaccine | BIOLOGICAL | Receive SOC mRNA SARS-CoV-2 vaccine IM |
| Diagnostic Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | BIOLOGICAL | Given IM |
GEO-CM04S1 is an investigational vaccine developed by GeoVax Labs, Inc. for protection against COVID-19 infection. It is a synthetic MVA-based SARS-CoV-2 vaccine currently in Phase 2 clinical development. It is being studied in patients with blood cancers, a population that may respond less well to standard COVID-19 vaccines.
GEO-CM04S1 is being developed to prevent COVID-19 infection, with a focus on patients who have blood cancers such as leukemia, lymphoma, and plasma cell myeloma. These patients often have weakened immune responses to conventional vaccines, so GEO-CM04S1 is being tested as an alternative vaccination strategy.
GEO-CM04S1 is made by GeoVax Labs, Inc., a biotechnology company whose common stock trades under the ticker symbol GOVX. GeoVax is the developer responsible for the vaccine's clinical program.
GEO-CM04S1 is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by the FDA. The Phase 2 trial is currently active and not recruiting, with a total of 63 participants enrolled.
GEO-CM04S1 is being evaluated in one clinical trial, NCT04977024, titled "SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer." This Phase 2 trial has an enrollment of 63 participants and is currently active but not recruiting.
Yes, GEO-CM04S1 is also known as the Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1. Both names refer to the same investigational vaccine developed by GeoVax Labs, Inc. for COVID-19.